Australian pharmaceutical company LTR Pharma has begun recruiting subjects in a bioequivalence clinical study of SPONTAN, a quick-acting nasal spray designed to treat erectile dysfunction (ED).

British scientists have discovered a fast-acting peptide that temporarily immobilises sperm and raises the possibility of a male pill, implant - or even a nasal spray - being available by 2021.

In early June LTR Pharma reported positive results from primary and secondary clinical studies for Spontan, which is a ...